SELLAS Life Sciences (SLS) 10-Q2022 Q1 Quarterly report

Filed: 12 May 22, 4:07pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: add, administered, alternative, announced, area, array, Asia, azacitidine, call, Carlo, carried, chronic, clarify, CLL, Collaboration, conflict, consummated, correlate, deducting, delivered, Delta, diligence, disagreement, dispute, disrupt, driven, endometrial, escalating, event, evolved, evolving, Ewing, examined, external, failure, flow, fulfill, GenFleet, goal, governmental, Greater, hypomethylating, immunology, inadequate, IND, inhibitor, institutional, Issuer, kinase, liable, longer, lose, lung, lymphocytic, lymphoma, Med, melanoma, metastatic, mg, modification, molecule, Monte, month, National, NMPA, nonperformance, occurrence, older, Omicron, oncology, onset, osteosarcoma, outlicensing, outreach, pediatric, primary, priority, prostate, protocol, provision, rare, reduce, rely, rhabdomyosarcoma, sarcoma, satisfactory, screening, selective, selectivity, Shanghai, shown, simulation, SLL, small, soft, staffing, strong, synergy, tissue, tolerated, toxicity, unchanged, uncollectible, underwriting, underwritten, utilizing, vast, venetoclax, voucher, week, workforce

Removed: absence, Abstral, adjuvant, adverse, alleged, allegedly, alleging, altered, amortized, amounting, anniversary, annually, assert, authorization, awarded, back, behalf, Biopharma, borrowing, calculating, California, challenge, civil, claim, claiming, collection, commensurate, commercially, competition, complaint, convenience, convention, coordinate, corporation, court, covering, credit, criminal, cure, customary, customer, defendant, Delaware, design, designated, determination, determining, DFS, disclose, distinct, District, duty, employed, enforceability, expiration, export, expression, failed, faith, feedback, fentanyl, fiduciary, finalized, forfeited, functioned, Galena, generic, geographic, good, goodwill, Herceptin, historically, identified, IHC, immunohistochemistry, impacted, improper, improvement, indemnification, insolvency, intermediate, involved, irrevocable, Jersey, joint, July, lawsuit, led, manufacturer, maximize, measure, meeting, mentioned, Merger, methodology, misleading, motion, negotiate, notice, November, October, open, operationally, order, organization, output, party, perpetual, predecessor, prejudice, previously, prohibited, projected, promised, promotional, purport, putative, ramp, rapidly, reach, reached, reduction, reevaluate, referenced, region, registered, rendered, resolution, responsible, reversed, satisfying, settlement, shareholder, showed, Simplifying, spread, spreading, stayed, steering, studied, sublingual, subscription, targeting, technological, timeline, TNBC, transferring, translational, trastuzumab, triple, Union, valid, validity, vest

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SLS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report of SELLAS Life Sciences Group, Inc., (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the Company’s financial condition and results of operations.


			By:						/s/ Angelos M. Stergiou

									Angelos M. Stergiou, MD, ScD h.c.
									President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)

									Date: May 12, 2022

A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.